Private Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Private Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$243K	–	148
2018 Q1	$243K	Hold	3,000	–	–	0.04%	114
2017 Q4	$268K	Hold	3,000	–	–	0.04%	124
2017 Q3	$279K	Buy	+3,000	New	+$265K	0.04%	132

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Private Asset Management's BMRN Position: Q2 2018 in Review

Private Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 3,000 shares — an estimated $243K sold.

Private Asset Management first reported a position in BMRN in Q3 2017 and held it in 3 quarters. The position peaked at $279K in Q3 2017. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Private Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Private Asset Management sold 3,000 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $243K.
Private Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 3 quarters.
Private Asset Management's BioMarin Pharmaceuticals position peaked at $279K in Q3 2017.
448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Private Asset Management's 13F filing for Q2 2018, filed 10 Jul 2018.